Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 2,511 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967 shares of the company’s stock, valued at $4,467,806.82. The trade was a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Glaukos Price Performance

Shares of Glaukos stock opened at $104.95 on Tuesday. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of -32.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The stock has a 50 day moving average price of $112.62 and a 200-day moving average price of $102.20. Glaukos Corporation has a one year low of $73.16 and a one year high of $130.23.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The company had revenue of $143.12 million for the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.40) EPS. Equities analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Ratings Changes

GKOS has been the subject of several analyst reports. The Goldman Sachs Group restated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a report on Friday, January 9th. Stifel Nicolaus upped their price target on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Truist Financial increased their price objective on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Wells Fargo & Company raised their price objective on shares of Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Needham & Company LLC boosted their target price on Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.69.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently made changes to their positions in the business. UMB Bank n.a. grew its holdings in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the last quarter. First Horizon Corp lifted its holdings in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Glaukos in the 4th quarter valued at about $28,000. Larson Financial Group LLC boosted its position in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares during the period. Finally, REAP Financial Group LLC purchased a new stake in Glaukos in the 3rd quarter valued at about $40,000. 99.04% of the stock is currently owned by institutional investors.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.